The Latest Breaking News from Diagnostics

Co-Diagnostics, Inc. (NASDAQ:CODX) shares plunged over 50% on Tuesday after the company announced a $7 million direct offering and a new Saudi-based joint venture.

Co-Diagnostics, Inc. (NASDAQ:CODX) shares are trading higher Monday after the company signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics and localize its Co-Dx PCR platform across the Middle East.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Quest Diagnostics Inc (NYSE:DGX) may be encountering what you might call a post-earnings digestion dance. Initially, DGX stock jumped higher, perhaps due to the algorithms and retail traders responding in unison to the better-than-expected results for the second quarter. But the next day, the security slipped, possibly as fund managers…

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

Co-Diagnostics Inc (NASDAQ: CODX) reported first-quarter revenue growth of 13.4% year-over-year to $22.7 million, beating the consensus of $20.17 million.

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

Co-Diagnostics (NASDAQ:CODX) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Co-Diagnostics will report an earnings per share (EPS) of $0.12.

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million of its common stock.